Pharmaceutical

AD/PD 2025: Reporting of first real-world data for Leqembi focuses on operational challenges and safety

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July 2024.

Apr 8, 2025 - 06:00
AD/PD 2025: Reporting of first real-world data for Leqembi focuses on operational challenges and safety
Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July 2024.
Read the original article

Tags:

Previous Article

EC approves extension of indication for Janssen-Cilag’s Darzalex

Next Article

RFK Jr shifts stance on MMR vaccine amid measles deaths

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Amicus receives FDA approval for Pompe disease therapy

Amicus receives FDA approval for Pompe disease therapy

Sep 29, 2023

Abbott glucose monitor readers could catch fire, FDA warns in recall notice

Abbott glucose monitor readers could catch fire, FDA wa...

Apr 7, 2023

ESC 2024: Beta blocker treatment paradigm shifts for myocardial infarction

ESC 2024: Beta blocker treatment paradigm shifts for my...

Sep 4, 2024